Navigation Links
Multidisciplinary treatment of glioblastoma multiforme can extend patient's life
Date:8/12/2010

Glioblastoma multiforme is the most common form of brain cancer; being an extremely serious type of the disease as currently, on diagnosis, the chances of survival of the patient is less than a year. In fact, its cause is not known nor the manner to prevent it. What is more, progress of patients suffering from this condition has hardly changed in 40 years, unlike other cancers such as, for example, infant leukaemia, for which the possibilities of recovery have risen dramatically.

The Hospital Universitario Donostia (at the city of Donostia-San Sebastin in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicols Samprn, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.

As Dr Samprn explained, each year there are between three and six cases of glioblastoma multiforme for every 100,000 inhabitants and, thereby, between 30 and 40 new cases correspond to the Hospital Donostia annually. It is not, therefore, an infrequent illness. The new protocol incorporated into the hospital analysed in this thesis puts forward a more multidisciplinary approach to the treatment of patients suffering from this type of cancer. The key figure at the hospital is the Neuro-oncological hospitalisation committee or team, on which neurosurgeons, neurologists, cancer experts, anatomical pathologists, radiologists and others serve; all specialists involved in the care of these patients. The idea is, thus, to provide a more personalised treatment and monitoring.

17 months

According to the thesis, this new multidisciplinary approach gives better survival rates; the usual average survival rate for a patient with glioblastoma multiforme having been 12 months, after the incorporation of this treatment it has risen to 17 months and a half.

The thesis also highlights a finding as regards determining factors for prognosis. As Dr. Samprn pointed out, the general health situation of the patient at the moment of the diagnosis is the most efficacious indicative factor when predicting the most favourable prognosis, whereas molecular studies have not provided conclusive results with respect to this prognosis.


'/>"/>

Contact: Amaia Portugal
a.portugal@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. CIHR team grant to fund multidisciplinary breast cancer survivorship studies
2. Stem Cell Treatment May Offer Hope Against Fatal Skin Disorder
3. NIH award will enable design of brain tumor treatment that captures migrating cancer cells
4. New antiviral drug shows promise for dramatic improvement in hepatitis C treatment
5. New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment
6. Surgery better than radiation, hormone treatments for some prostate cancer, study shows
7. Drug control efforts in Mexico reduce methamphetamine treatment admissions in Mexico and US
8. MicroRNA molecule increases number of blood stem cells, may help improve cancer treatment
9. Iron oxide nanoparticles becoming tools for brain tumor imaging and treatment
10. Ketamine Eased Depression in Treatment-Resistant Bipolar Disorder
11. New studies question vascular multiple sclerosis hypothesis and treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... Washington, D.C. (PRWEB) , ... June 23, 2017 ... ... temperature during cooking is essential, and two new videos highlight the importance of ... Extension Specialist Christine Bruhn, Ph.D., who has done extensive research on consumer food ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ... the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people ... the Biggert-Waters Act was enacted to reflect the actual risk in flood zone ...
(Date:6/23/2017)... Gilmer, TX (PRWEB) , ... June 23, 2017 , ... ... consultations to residential and business clients throughout eastern Texas, is announcing the launch of ... , Recent breast cancer statistics in the United States reveal that an estimated ...
(Date:6/22/2017)... IN (PRWEB) , ... June 22, 2017 , ... ... benefits advisory organization, is pleased to welcome Whipple & Company as its newest ... the clear purpose of balancing their clients’ risk while tailoring optimized benefit packages ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... it will be presenting at the 7th annual LD Micro Invitational ... Raphael , CEO, of DarioHealth will be giving the presentation and ... June 6th & 7th, 2017 at the Luxe Sunset Bel Air ... space. About LD Micro LD ...
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
Breaking Medicine Technology: